Stifel Starts Nivalis Therapeutics (NVLS) at Buy

Stifel initiates coverage on Nivalis Therapeutics (NASDAQ: NVLS) with a Buy rating and a price target of $23.00.

Analyst Thomas Shrader commented, "Nivalis Therapeutics is developing N91115 for Cystic Fibrosis (CF). Preclinical data for the drug suggests it both increases the stability of the CFTR channel impaired in CF patients and reduces the inflammation that continually damages the CF lung. N91115 appears safe and should combine well with most other therapeutics marketed and being developed to help CF patients."

For an analyst ratings summary and ratings history on Nivalis Therapeutics click here. For more ratings news on Nivalis Therapeutics click here.

Shares of Nivalis Therapeutics closed at $16.60 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• MarineMax (HZO) PT Lowered to $35 at Stifel
• Macquarie Upgrades ASM Pacific Technology (522:HK) (ASMVY) to Outperform